Please login to the form below

Not currently logged in
Email:
Password:

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

Roche Avastin bevacizumab cancerRoche's blockbuster cancer drug Avastin has added to its list of indications in the US with a new approval for its use in people with metastatic colorectal cancer (mCRC).

The drug is already licensed for use in combination with chemotherapy as a first-line treatment for people with the condition, but Avastin (bevacizumab) can now also be used alongside a different chemotherapy as a second-line treatment if the disease progresses.

“The majority of people diagnosed with metastatic colorectal cancer receive Avastin plus chemotherapy as their initial treatment,” said Dr Hal Barron, Roche's chief medical officer and head of global product development.

“These people now have the option to continue with Avastin plus a new chemotherapy after their cancer worsens, which may help them live longer than changing to the new chemotherapy alone.”

The FDA approval is based on the phase III ML18147 study, data from which demonstrated that people with mCRC who continued to receive Avastin in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy lived longer than people who switched to chemotherapy alone.

The median progression-free survival for people in the Avastin arm of the trial was 5.7 months compared to 4.1 months in the non-Avastin arm - a reduction in risk of progression-free survival of 32 per cent.

These results have already seen Avastin's European product information updated in December, 2012, allowing people with mCRC who received the Avastin regimen as a first-line treatment to continue to receive Avastin as part of a second-line treatment.

The latest FDA approval is the second major regulatory milestone for Avastin in recent months after it was cleared in the EU for the treatment of recurrent ovarian cancer in November, 2012.

In addition to its colorectal cancer indications in the US, it is also approved to treat non-small cell lung cancer (NSCLC), kidney cancer and progressive glioblastoma, while in Europe it is available for use in the treatment of advanced stages of breast cancer, colorectal cancer, NSCLC, kidney cancer and ovarian cancer.

The drug is one of Roche's most successful products and achieving sales of 2.81bn Swiss francs (about €2.25bn) during the first six months of 2012.

24th January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Excel Communications

Excel Communications is a world class training and development company facilitating tailored, in-house learning events including coaching, workshops and development...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics